Compare Coupang Inc (CPNG) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coupang Inc vs Gilead Sciences, Inc. — how do they compare? Coupang Inc trades at $15.79 (market cap $27.70B), while Gilead Sciences, Inc. trades at $150.89 (market cap $182.40B). The key difference: Gilead Sciences, Inc. is far larger — about 6.6× Coupang Inc's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Coupang Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Coupang Inc for 55 Days and Gilead Sciences, Inc. for 111 Days on average.
| CPNG | GILD | |
|---|---|---|
Market Cap | $27.70B | $182.40B |
Volume | 27,703,608 | 4,469,821 |
Sector | Consumer Cyclical | Health |
52-Week High | $32.47 | $155.80 |
52-Week Low | $13.75 | $116.74 |
Typical Hold Time | 55 Days | 111 Days |
Enterprise Value | $27.22B | $205.46B |
Dividend Yield | — | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CPNG trades at $15.83, up 6.89% over 24 hours, with a bullish technical signal from moving averages and ADX. The company reported $34.53B revenue in 2025 with a net income of $208M, though recent quarters show earnings misses. Analyst consensus is strongly bullish with a $25.25 price target, and cash flow from operations remains positive at $1.77B.
The outlook is mixed: strong revenue growth and analyst support offer upside, but negative net income margin and high P/E of 184.18 signal overvaluation risks. Key risks include competitive pressure from MercadoLibre and Alibaba, and a projected net loss of $767M in 2026. Institutional sentiment is positive, but earnings volatility requires caution.
Gilead Sciences (GILD) trades at $150.72, up 2.64% with a bullish technical signal and strong analyst support (65.5% buy ratings). Recent quarterly earnings have consistently beaten expectations, though Q2 2026 showed a significant loss. The company maintains robust operating cash flow ($10.02B in 2025) and is expanding HIV prevention access through new partnerships, positioning for growth despite a negative net income margin of -10.64%.
Outlook is cautiously optimistic with a consensus price target of $151.57, slightly above current levels. Key opportunities include pipeline advances in oncology and HIV treatments, while risks involve profitability volatility, high debt levels, and competitive pressures. The stock's valuation metrics suggest moderate pricing relative to earnings but elevated on sales and book value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Coupang Inc
Coupang Inc is an e-commerce company. The company sells apparel, electronics, footwear, food products, furniture, nutritional supplements, and other products. Its segments include Product Commerce and Growth Initiatives.
Read more on CPNG →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
